Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and ...

Dr Vamsi Veeramachaneni: Nandita Vijayasimha, Bengaluru Tuesday, July 22, 2025, 08:00 Hrs [IST] Genomic profiling is n ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...

Price cut persuades NICE to back AstraZeneca’s Tagrisso for first-line use in lung cancer, but there’s bad news for drugs from Celgene and Pfizer ...

The Democrats running for California governor have spent the spring and summer working to win over the powerful donors and interest groups who could help them squeak through a competitive ...